19
total announcements
LAURUSLABS.NS · 15 min delayed
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about Schedule of meet for an Investor Conference on September 07, 2026, at Hyderabad. The meeting is subject to change due to exigencies and no unpublished price sensitive information will be shared.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting, to be held on August 19, 2026, at the 22nd Annual Global Investor Conference in Mumbai.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about Intimation of ESG Score given by NSE Sustainability Ratings and Analytics Limited. The company has been assigned an Environmental, Social, and Governance Score (ESG Score) of 63 out of 100 for FY 2026.
Laurus Labs Limited
Laurus Labs Limited has hosted a Q1 FY27 earnings conference call, discussing strong growth momentum, with revenue of INR2,026 crores, a 29% growth, and EBITDA margins expanding to 31.8%. The company has also signed a development and commercial agreement with Aarvik Therapeutics for 2 ADC molecules and onboarded a big pharma client.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about the allotment of 62,635 equity shares to eligible employees on exercise of ESOPs under Laurus Employees Stock Option Scheme 2016, Laurus Employees Stock Option Scheme 2018, and Laurus Labs Employees Stock Option Scheme 2021.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about an update on the Composite Scheme of Arrangement. The Hon'ble National Company Law Tribunal, Amravati Special Branch has directed the Petitioner Companies to serve the notice of the hearing of the Petition in Form No. CAA-3 to concerned authorities/regulators and other stakeholders. The next date of hearing is September 10, 2026.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about the publication of unaudited financial results for the quarter ended June 30, 2026, in compliance with Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about the link of the recording of the Q1 FY27 Results Conference Call hosted on July 24, 2026.
Laurus Labs Limited
Laurus Labs Limited has announced its Q1 FY27 results, with revenue at ₹ 2,026 Cr, representing 29% growth, and EBITDA at ₹ 644 Cr, representing 66% growth. The company has achieved strong operating performance despite macroeconomic volatility, with improved capacity utilization and operating leverage.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about Presentation to the Investors/Analysts on the Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2026. The presentation is for the Investors/Analysts call scheduled on July 24, 2026.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange regarding Change in Director(s) of the company. Dr. Rajesh Koshy Chandy has retired as an Independent Director with effect from July 26, 2026.
Laurus Labs Limited
Laurus Labs Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, showing a net profit of ₹361.99 crore.
Laurus Labs Limited
Laurus Labs Limited has received certificates from KFin Technologies Limited, the Registrar and Share Transfer Agent, under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about Schedule of meet for Q1 FY27 Earnings conference call invite for the call scheduled on July 24, 2026.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about the completion of the tenure of Independent Director, Mrs. Aruna Bhinge, effective July 6, 2026.
Laurus Labs Limited
Laurus Labs Limited has received a reaffirmation of its credit ratings from CARE Ratings Ltd., reflecting the company's sustained improvement in performance in FY26, marked by growth in total operating income, uptick in profitability margins, and strengthening of debt coverage indicators.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange about the appointment of two independent directors at its 21st Annual General Meeting.
Laurus Labs Limited
Laurus Labs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 02, 2026, and submitted the Exchange a copy of Srutinizers report along with voting results.
Laurus Labs Limited
Laurus Labs Limited has closed its trading window for dealing in its securities from July 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026, as per SEBI (Prohibition of Insider Trading) Regulations, 2015.